Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
American Society of Clinical Oncology (ASCO)
Online
2022-12-13
DOI
10.1200/jco.22.02355
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hodgkin lymphoma: 2023 update on diagnosis, risk‐stratification, and management
- (2022) Stephen M. Ansell AMERICAN JOURNAL OF HEMATOLOGY
- 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
- (2021) Elena Gerhard‐Hartmann et al. BRITISH JOURNAL OF HAEMATOLOGY
- Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study
- (2021) Julien Lazarovici et al. BLOOD
- Unfolding the potential of anti‐programmed cell death protein 1 blockade in Hodgkin lymphoma – combination and personalisation?
- (2021) Paul J. Bröckelmann BRITISH JOURNAL OF HAEMATOLOGY
- Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
- (2021) Maria A. Garcia-Marquez et al. LEUKEMIA
- Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma
- (2021) Angie Mae Rodday et al. JAMA Network Open
- Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
- (2021) Pier Luigi Zinzani et al. Blood Advances
- Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
- (2020) Paul J. Bröckelmann et al. JAMA Oncology
- Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group
- (2020) Stefanie Kreissl et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma
- (2020) Pamela Blair Allen et al. BLOOD
- Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
- (2020) Sarah Reinke et al. BLOOD
- Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
- (2019) Radhakrishnan Ramchandren et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma
- (2019) Bastian von Tresckow et al. LEUKEMIA & LYMPHOMA
- Balancing risk and benefit in early-stage classical Hodgkin lymphoma
- (2018) Paul J. Bröckelmann et al. BLOOD
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Treatment of Hodgkin Lymphoma: A 50-Year Perspective
- (2014) George P. Canellos et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
- (2012) Bastian von Tresckow et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started